Skip to main content
. 2021 Sep 29;9:646997. doi: 10.3389/fped.2021.646997

Figure 2.

Figure 2

Timeline illustrating the development of our patient's clinical phenotype and improvement following dupilumab. Interventions are indicated in red. HSV, herpes simplex virus; IgE, immunoglobulin E; IVIG, intravenous immunoglobulin; MRSA, methicillin resistant Staphylococcus aureus; TMP/SMX, trimethoprim/sulfamethoxazole.